Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.
|13/06/2017||13/07/2017||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
|NCPE Assessment Process||Ongoing|
|Rapid review Re-commissioned||15/06/2020|
|Rapid review completed||14/07/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegylated liposomal irinotecan compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||14/07/2020|
|Pre-submission consultation with Applicant||07/09/2020|
|Full HTA Submission received from Applicant||04/03/2021|
|Preliminary review sent to Applicant||02/09/2021|
|Current status||Awaiting response from Applicant|